Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.

about

Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.Clinical Pharmacokinetics of Paritaprevir.Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

P2860

Q38893128-15B626D3-0C37-43C6-A521-5EDFDF56D362 Q39150134-38A08834-86F3-48CB-8158-A0F545665655 Q39301797-9D554945-8CC5-4708-94C3-7733827DCD5B Q48223561-9D6C0BD5-2E54-49A1-8171-C6291A680492

P2860

Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.

Item

http://www.wikidata.org/entity/Q40674760

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.

@en

type

Item

label

Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.

@en

prefLabel

Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.

@en

P1476

Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.

@en

P2093

Aimee Reed

http://www.w3.org/2001/XMLSchema#string

Amit Khatri

http://www.w3.org/2001/XMLSchema#string

Anthony J Lee

http://www.w3.org/2001/XMLSchema#string

Jianwei Shen

http://www.w3.org/2001/XMLSchema#string

Kennan Marsh

http://www.w3.org/2001/XMLSchema#string

Michael Serby

http://www.w3.org/2001/XMLSchema#string

Olga Kavetskaia

http://www.w3.org/2001/XMLSchema#string

Rajeev Menon

http://www.w3.org/2001/XMLSchema#string

Volker Fischer

http://www.w3.org/2001/XMLSchema#string

Xiaomei Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical significance of hepatitis C virus genotypes

Replication of hepatitis C virus

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

Evolving epidemiology of hepatitis C virus

Boceprevir for untreated chronic HCV genotype 1 infection

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.

In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

P304

1164-1173

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.115.067488

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

303097376

http://www.w3.org/2001/XMLSchema#string

P698

27179127

http://www.w3.org/2001/XMLSchema#string

Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.

about

P2860

P2860

Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698